First US patient gets total heart replacement with CARMAT deviceAn experimental artificial heart developed by French medical device specialist CARMAT has been implanted into the first of Share XFirst US patient gets total heart replacement with CARMAT devicehttps://pharmaphorum.com/news/first-us-patient-gets-total-heart-replacement-with-carmat-device/
Boehringer, Lilly hail Jardiance data in hard-to-treat heart failureBoehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance Share XBoehringer, Lilly hail Jardiance data in hard-to-treat heart failurehttps://pharmaphorum.com/news/boehringer-lilly-hail-jardiance-data-in-hard-to-treat-heart-failure/
AZ drug for hard-to-treat heart failure has mixed results in trialAstraZeneca has reported the first phase 2 results with a drug for heart failure with preserved ejection fraction Share XAZ drug for hard-to-treat heart failure has mixed results in trialhttps://pharmaphorum.com/news/az-drug-for-hard-to-treat-heart-failure-has-mixed-results-in-trial/
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s JardianceAstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will Share XFarxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiancehttps://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/
Novo Nordisk crowns cell therapy pipeline with $598m Heartseed dealNovo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed Share XNovo Nordisk crowns cell therapy pipeline with $598m Heartseed dealhttps://pharmaphorum.com/news/novo-nordisk-crowns-cell-therapy-pipeline-with-598m-heartseed-deal/
Pharma poised to cash in on ‘long COVID’ symptomsWhile there’s hope that vaccination campaigns may bring the pandemic under control, “long COVID” side effects may continue Share XPharma poised to cash in on ‘long COVID’ symptomshttps://pharmaphorum.com/news/big-pharma-could-cash-in-on-long/
FDA approves Bayer/Merck & Co heart failure drugBayer and Merck & Co’s heart failure drug vericiguat has been approved by the FDA under the brand Share XFDA approves Bayer/Merck & Co heart failure drughttps://pharmaphorum.com/news/competition-mounts-in-heart-failure-fda-approves-bayer-merck-co-drug/
Boehringer, Lilly’s Jardiance tries to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance tries to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
NICE backs AZ’s Forxiga for heart failureJust a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE Share XNICE backs AZ’s Forxiga for heart failurehttps://pharmaphorum.com/news/nice-backs-azs-forxiga-for-heart-failure/
